SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community anticipates further upside, with some eyeing previous highs and staking opportunities. Discussion is centered around potential rallies and the possibility of outperforming other major cryptocurrencies. Talk also highlights treasury strategies and corporate adoption as potential catalysts for growth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle ($ORCL) is trending due to news of a significant cloud computing deal with OpenAI, sparking both excitement and skepticism within the community. Some investors believe the deal will propel ORCL to new heights, while others question the financial viability and sustainability of OpenAI's involvement and consider the surge a potential bubble. Community members are actively debating the long-term implications of the partnership, with some highlighting potential risks and an insider lock-up ending soon.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty is trending amid discussions about its upcoming DEX launch in November and a trading bot that generates revenue. The community is also buzzing about a potential airdrop of QKITTY.X and BROKE.X tokens. Some users highlight that the project emphasizes transparency and has a trusted developer.

Wearable Devices Ltd. engages in the development of a non-invasive neural input technology that allows operation and control of digital devices using subtle finger movements and fingertip pressure. It offers Mudra band, a neutral input wristband. The company was founded by Asher Dahan, Guy Wagner, and Leeor Langer in March 2014 and is headquartered in Yokne'am Illit, Israel.

Wearable Devices Ltd

WLDS is trending due to a recently granted U.S. patent for its gesture and voice-controlled interface technology, sparking discussions about potential applications in AI wearables and possible acquisition by major tech companies like Apple. The community is actively debating the stock's potential for a multi-day run, buyout speculation, and potential short squeeze, while also weighing concerns about possible dilution. Some traders are drawing comparisons to other high-flying stocks.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to a special dividend announcement in the form of warrants, sparking debate about its implications. While some community members see this as a catalyst for a potential short squeeze and long-term value, others express concerns about potential dilution and market manipulation. The stock's volatile price action and heavy trading volume are fueling active discussions about its future direction and the impact of the warrant distribution.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending downwards, driven by an analyst downgrade and concerns over increasing competition from Amazon and Netflix, leading to a significant sell-off. Community sentiment is largely negative, with many investors expressing frustration and questioning the company's leadership and strategic direction. Some investors believe the stock is oversold and ripe for a bounce, while others fear further declines and are considering exiting their positions.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna's NYSE debut has traders discussing its valuation relative to competitors like Affirm, with some pointing to its potential for long-term growth in the BNPL sector. Concerns about the company's business model and potential regulatory scrutiny are also circulating. The IPO's initial price action and allocation sizes are driving immediate conversation within the community.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as investors debate its future amidst competition from companies like Klarna, with some seeing it as a value trap and others anticipating a rise due to buybacks and potential rate cuts. Community discussions revolve around the stock's inability to sustain gains and frustration with its performance compared to other fintech and tech stocks. Some analysts believe PayPal's value is suppressed and are waiting for a breakout.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors weigh competitive pressures in the AI cloud space, particularly after Oracle's recent gains, despite positive developments with Netflix and autonomous driving. The community is actively discussing whether recent drops represent a buying opportunity or a sign of further declines, with debates around fair valuation and future growth prospects. Broader market factors and potential impacts from economic data releases are also influencing sentiment.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending due to discussions surrounding its potential Alzheimer's drug and recent clinical data, with community members debating the efficacy and safety profile compared to existing treatments. Some traders are pointing to potential short squeezes and heavy manipulation, while others express concerns about the company's history and await EMA approval. The stock's volatile price movement is fueling speculation about its future.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the Health and Human Services Department, led by Robert F. Kennedy Jr., plans to "drastically" cut federal funding for domestic HIV prevention.While cuts have not been finalized, the Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b?mod=Searchresults_pos1&amp;page=1&amp;mod=article_inline&amp;adobe_mc=MCMID%3D74537243080012175182679892959762943330%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1742440495&amp;_gl=1*1myqz7*_gcl_au*NTUzNDY5MDY4LjE3MzUyMTA0MzI.*_ga*MTg1Mzg3MjI1NS4xNzE4OTcyNDYz*_ga_K2H7B9JRSS*MTc0MjQ0MDIzNy4yNi4xLjE3NDI0NDA0OTMuNjAuMC4w">reported</a>, citing people familiar with the matter, that they could be announced soon as part of the Trump administration's broader budget reductions at the Centers for Disease Control and Prevention.Gilead, which has a portfolio of HIV prevention treatments such as Biktarvy and Descovy, risks a hit to revenues if the report turns out to be true.However, retail investors and Wall Street analysts remain largely unfazed for now.Retail sentiment for Gilead on Stocktwits climbed further into the 'extremely bullish' zone on Wednesday, with message volume up 57% following the news.&nbsp;<figure class="image"><img style="aspect-ratio:1318/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GILD_sentiment_and_message_volume_as_of_March_19_png_baa27803b8.webp" alt="GILD sentiment and message volume as of March 19.png" width="1318" height="302"><figcaption>GILD sentiment and message volume as of March 19. | source: Stocktwits</figcaption></figure>Observers on the platform cited Gilead's dominance in HIV treatments, growing oncology presence, and strong free cash flow as reasons to hold on to the stock.<stembedurl>https://stocktwits.com/Bitcoin333/message/608542775</stembedurl><stembedurl>https://stocktwits.com/skcots131313/message/608543583</stembedurl>According to The Fly, JPMorgan acknowledged that the WSJ report is "clearly not a positive" but says the potential cuts wouldn't impact access to PrEP (pre-exposure prophylaxis). The firm noted that the CDC doesn't reimburse PrEP drugs but funds research and education.&nbsp;The research firm remains bullish on Gilead's lenacapavir — a twice-yearly injectable HIV-1 capsid inhibitor — as a key growth driver and maintains an 'Overweight' rating on the stock.Oppenheimer sees Gilead's pullback as a reaction to uncertainty but doesn't view the funding concerns as a material risk. The firm estimates PrEP revenues account for just 8% of Gilead's total sales, with Medicaid representing an even smaller fraction.&nbsp;It expects early lenacapavir adoption mostly from private insurers and reiterated an 'Outperform' rating with a $132 price target.If approved by the Food and Drug Administration, Morgan Stanley reportedly estimates that lenacapavir could generate annual sales of over $6 billion by 2030.According to Koyfin data, Gilead stock currently trades at a 13.5x forward earnings multiple, compared to Eli Lilly's 36.1x and Amgen's 15.3x.Shares of Gilead are up 16% this year, outperforming the NASDAQ Biotechnology Index's 3% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Equity

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.


Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-q4-2024-earnings/chdgfF2RyA">hope</a> in the clinical-stage biotech company.The company has gained traction for its lead candidate,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-on-phase-2-obesity-drug-trial-data/c7zs1ZqRP8">pemvidutide</a>, a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH. In a mid-stage trial, the drug showed that it helped patients reduce their weight by more than 15%.&nbsp;At its R&amp;D Day last week, Altimmune provided more cheer as it unveiled plans to test pemvidutide for treating alcohol use disorder and alcohol-associated liver disease in the second and third quarters of this year.According to The Fly, Evercore ISI said it likes Altimmune's latest expansion and suggested that pemvidutide could rake in more revenue for the new goals than MASH, as 35 million people in the U.S. alone suffer from alcohol use disorder and alcohol-associated liver disease.The research firm added that there is some preclinical and anecdotal evidence to support its thesis.Assuming all goes well, Altimmune will need to fund a Phase 3 program later this year in addition to the AUD/ALD studies, said Evercore, which has an Outperform rating on the shares and a price target of $25.Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. Last year's key&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">C-suite hire</a> at a "pivotal time" for Altimmune bolstered their belief.A Betaville&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.msn.com/en-us/money/companies/altimmune-soars-amid-takeover-speculation/ar-AA1AWioc">report</a> suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms — one FTSE-100 listed, one German, and one U.S.-based — may be involved.<figure class="image"><img style="aspect-ratio:1320/710;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_Stocktwits_poll_on_March_18_png_3a31e58347.webp" alt="ALT Stocktwits poll on March 18.png" width="1320" height="710"><figcaption>ALT Stocktwits poll on March 18. | source: Stocktwits</figcaption></figure>One bullish user said it's "not if, but when [a deal happens]. Too much TAM [total addressable market] for this pipeline of a molecule."<stembedurl>https://stocktwits.com/artiebet/message/608157454</stembedurl>Another user speculated a buyout could happen "within three months," noting the stock is "heading north each week" with "higher lows, higher highs."<stembedurl>https://stocktwits.com/LiveNow1225/message/608159514</stembedurl>Altimmune's stock, which was&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Altimmune Shares Sink In 2025, But Retail Traders Are Optimistic About A Buyout

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.


Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended gains in after-hours trading. Retail buzz on Stocktwits surged, hitting a three-month high.The clinical-stage biopharma company reported a net loss of $23.2 million, or $0.33 per share, for Q4 2024 — an improvement from a $31.6 million loss ($0.54 per share) a year ago.&nbsp;Altimmune ended the year with $132 million in cash and investments, which it expects to fund operations well into the second half of 2026, covering key milestones, including the Phase 2b readout for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) next quarter.CEO Vipin K. Garg said the IMPACT trial was one of "the fastest enrolling biopsy-driven Phase 2b MASH trials, reflecting pemvidutide's appeal due to its potent reduction of liver fat and body weight.""We are confident it will achieve statistically significant improvements in both MASH resolution and fibrosis at trial readout."Altimmune also said it had secured FDA clearance for two additional indications submitted under Investigational New Drug (IND) applications in Q4, with Phase 2 efficacy studies set to begin mid-2025. The company plans to unveil details at its virtual R&amp;D Day on March 13.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume soaring 273% in the 24 hours leading to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_sentiment_and_message_volume_Feb_27_1ee28571fe.png" alt="ALT sentiment and message volume Feb 27.png" width="1316" height="316"><figcaption>ALT sentiment and message volume Feb 27 | source: Stocktwits</figcaption></figure>One user predicted a sharp rally to $50, interpreting comments from Altimmune's chief scientific officer that pemvidutide "is the best drug for many indications."<stembedurl>https://stocktwits.com/romanaround/message/606129604</stembedurl>Another speculated on the new INDs, saying they could be for dyslipidemia (or hypertriglyceridemia) and Cirrhosis.<stembedurl>https://stocktwits.com/Cryptobearcat/message/606145193</stembedurl>Altimmune's lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH.&nbsp;The stock drew attention in December after being <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI).Shares of Altimmune are down over 12% year-to-date.&nbsp;According to Koyfin data, eight of the nine analysts covering the stock rate it a 'Buy' or 'Strong Buy,' while one has a 'Hold' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

Shares of Altimmune, Inc. climbed early on Thursday, recovering from a nearly 6% drop in the previous session, drawing significant retail attention.&nbsp;The stock became one of the top three trending symbols on Stocktwits during early trading after the company announced its inclusion in the Nasdaq Biotechnology Index ($NBI) starting Dec. 23.<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">Altimmune</a>, a clinical-stage biotech firm, is currently developing pemvidutide for obesity and metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;CEO Vipin Garg said, “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company.”“With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year,” he added.The Nasdaq Biotechnology Index, established in 1993, tracks the performance of Nasdaq-listed biotech and pharmaceutical companies that meet strict criteria such as market capitalization, trading volume, and seasoning requirements.&nbsp;The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.On Stocktwits, retail sentiment for Altimmune shifted from ‘neutral’ to ‘extremely bullish,’ accompanied by a sharp rise in message volume.&nbsp;<stembedurl>https://stocktwits.com/romanaround/message/597152901</stembedurl><stembedurl>https://stocktwits.com/Designed2Gain/message/597160936</stembedurl>A poll on the platform revealed that 52% of retail investors believe the NBI addition will provide a significant long-term boost to the stock, while 22% expect minimal impact.<a href="https://stocktwits.com/symbol/ALT">Altimmune’s shares</a> got a boost last month following better-than-expected quarterly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/altimmune-q3-loss-narrows/cJ40TqmROm">earnings</a> and positive updates on pemvidutide.&nbsp;The company reported a successful FDA meeting that finalized its Phase 3 obesity program design, with no major safety concerns raised.&nbsp;Analysts like H.C. Wainwright’s Patrick Trucchio have expressed confidence in the drug’s differentiation within the GLP-1 agonist space, citing robust efficacy attributes and a well-defined clinical program.Still, Altimmune’s stock remains down nearly 30% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Nasdaq company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire WALTHAM, Mass., Dec. 18, 2024 WALTHAM, Mass., Dec. 18, 2024...

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial...

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Record DANYELZA net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of...

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$KLAR IPO day is upon us, how are you playing it?

Stocktwits

 IPO day is upon us, how are you playing it?

NBI
NASDAQ Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Latest NBI News

NBI NASDAQ Biotechnology